Mandate

Vinge advises ABGSC in connection with EQL Pharma’s inaugural bond issuance

January 24, 2025 Banking and Finance

Vinge has advised ABG Sundal Collier in connection with EQL Pharma AB (publ)’s ( “EQL”) inaugural issuance of SEK 350,000,000 senior secured bonds within a framework of up to SEK 700,000.

The bonds carry a floating interest rate of STIBOR 3M + 4.00% and have a tenor of three years. EQL intends to apply for admission to trading of the bonds on Nasdaq Transfer Market and the corporate bond list of Nasdaq Stockholm. The net proceeds from the issuance will be used to finance the acquisition of a portfolio with original pharmaceuticals, repayment of existing financial indebtedness and for general corporate purposes.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers, August Ahlin and Sara Jansson.

Related

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026

Vinge advises Consolid Equity in connection with the establishment of Petra Group

Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026

Vinge has advised Scandic on new credit facilities with SEK 7.5 billion credit facilities

Vinge has represented Scandic Hotels Group AB (publ) in connection with a facilities agreement for SEK 7,500,000,000 with a syndicate of banks, arranged by DNB Carnegie Investment Bank AB and Nordea Bank Abp, filial i Sverige.
July 08, 2026